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Abstract Primary prevention of cardiovascular disease
should begin with a detailed metabolic study of our patients
who must follow a nutritional therapy. Recently, new
guidelines ESC/EAS 2011 on the treatment of dyslipidemia
have been drawn up, according to which it is possible to
arrive at desirable values of cholesterol and triglycerides
with a synergy between drug treatment and adequate diet
therapy. At this time, Mediterranean diet has been under-
going a radical transformation: there is hyperalimentation of
the Mediterranean diet in all its components. The effective-
ness of the Mediterranean diet on the reduction of lipids has
been demonstrated, and the problem is how to implement this
diet in the general population and dyslipidemic patients.
Certainly, awareness, education of their nutritional status,
suitable food and portions can increase adherence to diet.
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Introduction
The significant results that have been recorded on the
improvement of the lipid profile in dyslipidemic patients
are due to the increase of a therapeutic strategy in their
diet alongside of drug therapy. In June 2011, new guide-
lines on the management of dyslipidemia were drawn up by
the European Society of Cardiology (ESC)/European
Society for Atherosclerosis (EAS) 2011, which stated that
the synergy among an adequate diet, therapy and drug
treatment might be appropriate to achieve desirable levels
of cholesterol and triglycerides. In Italy, patients with
different forms of dyslipidemia make up 20 % of the
population. The same statistical reality applies to people
affected by metabolic syndrome, who make up 30 % of
Italy’s population and consist mainly of people who live in
the southern regions, mostly females.
Studies conducted on patients in North America have
shown that while the standard pharmacological interven-
tion reduces total cholesterol by 5–7 %, those who were on
a low-cholesterol diet saw a reduction in total cholesterol
by 10–12 % [1]. The data from the ‘‘Seven Countries
Study’’, which later expanded to 18 various countries,
showed that saturated fat, the introduction of dietary cho-
lesterol, and CHD mortality were directly related to each
other. Later, the data from the Oslo Study was added,
showing that a decreased intake of saturated fat and the
increased consumption of polyunsaturated fats reduced
mortality and/or morbidity of cardiovascular diseases (Oslo
Study) [2].
In countries such as Finland, the USA, New Zealand and
Australia, extensive campaigns were carried out on topics
such as fighting against smoking and hypertension, which
were supported by central governments, leading to a sig-
nificant and steady reduction in cholesterol levels and
mortality resulting from coronary heart disease.
Spreading awareness about the risks that increase the
chance of cardiovascular disease, with regard to average
heart problems, can motivate people to implement positive
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changes in their diet. However, asking a population to
adopt nutritional habits and putting into practice the advice
provided by the dietary recommendations and made by the
international scientific community seem to be a significant
challenge. Although health education campaigns are
growing steadily throughout the world, we have yet to
define the most effective strategies that can lead to better
results in the actual prevention of cardiovascular disease
along with the reduction of morbidity and mortality.
Pediatricians should play a key role in initiating a cor-
rect and continuous nutritional education from early
childhood, so as to then influence the future behavior of the
child. This is something that requires the involvement of
the parents or guardians, who are responsible for making
those ‘‘alimentary decisions’’ for their child’s future [3].
Concerning the dietary recommendations addressed to the
population, they should adopt and implement these strate-
gies to facilitate a healthy lifestyle. This can be achieved in
many ways with help from government facilities, schools,
food industries and restaurants. Strategies should focus on
education, production, composition and distribution in
order to induce the consumption of such foods recom-
mended by the American Heart Association of 2006 [4]
(Table 1) that are appropriate for the general population
worldwide, which includes adults and children above 2
years of age.
New guidelines: ESC/EAS 2011 for the management
of dyslipidemia
Recently, the guidelines of the ESC and EAS on lipid
disorders have been published in the European Heart
Journal of Atherosclerosis. This is a long-awaited docu-
ment from the European medical community that marks an
important update for clinical practice regarding the man-
agement of cardiovascular risk in primary and secondary
prevention. According to the guidelines, the estimated
cardiovascular risk remains a key factor in the framing of
the patient’s diet and subsequent management. It recom-
mends the SCORE model, which defines high-risk subjects
as those who have an odds of fatal events [0.5 % for the
year and over the next 10 years [5]. Approximately, the
conversion factor between the SCORE and probability of
fatal and no-fatal events is 3, so a score of 0.5 SCORE is
the probability of having 1.5 % of cardiovascular events
for a year. Also, this score includes the calculation of risk
values of HDL cholesterol which can significantly change
the condition of risk for the same SCORE. Most important
is the calculation of risk in young and old people. The
overall risk seems to be low because of young age, even in
those who suffer very high risk factors. In this case, the
assessment of relative risk—the relationship between per-
ceived risk and the risk of individuals of the same age but
with no risk factors—may indicate a risk, however, much
higher than expected and, therefore, recommend the
implementation of those lifestyles that can reduce the odds
of events by keeping under control over the following
decades. Similarly, in old persons, because of the burden of
age, the overall risks are generally higher and, therefore,
the aggressiveness of the interventions should consider this
issue more seriously, contextualizing each case in accor-
dance with the characteristics of old patients.
As for the new recommendations on the assessment of
lipid parameters, all men over 40 years and women over
50 years should be screened for lipids, which should be
anticipated in individuals with family history of premature
ischemic heart disease and in the presence of other risk
factors such as hypertension, diabetes, obesity, dyslipi-
demia, familial autoimmune disease or chronic renal
failure. Lipid screening should include the following para-
meters: total cholesterol, triglycerides, HDL and LDL,
according to the Friedewald formula (if triglycerides are
\400 mg/dl). Therefore, the guidelines recommend other
Table 1 Recommendations for diet and lifestyle for the reduction of cardiovascular risk of American Heart Association (AHA) in 2006
Balanced calorie intake and physical activity to achieve or maintain a healthy body weight
Rich in carbohydrates and fruit diet
Choose whole grains and fiber-rich foods
Consume fish, especially oily fish at least twice a week
Limit your intake of saturated fatty acids \7 % energy intake, trans fatty acids to \1 % and cholesterol \300 mg per day by assuming:
Lean meats and vegetable alternatives
Milk and dairy products skimmed or 1 % fat or low fat
Minimize partially hydrogenated fat intake
Minimize your intake of foods and beverages with added sugar
Choose foods and cook with little or no salt
Moderate use of alcohol, if allowed
For meals eaten outside, follow the same recommendations
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indicators only in special cases, although have being
recognized their validity such as the determination of
ApoB or relationship ApoB/ApoA1 or lipoprotein a. The
dosage of triglycerides should be made after at least 12 h,
and it is not influenced by the meal for the other
parameters. These recommendations have been reached as
a result of the undisputed evidence of the ongoing rela-
tionship between LDL reduction and reduction of mor-
tality and morbidity.
The LDL are the therapeutic targets and their levels
should be \70 mg/dL in those patients with a very high
risk. Particularly, all subjects with documented cardiovas-
cular disease, diabetes, chronic renal failure or SCORE
[1 % per year (the category of very high risk) should
reach the target \70 mg/dl. In subjects with high risk
(score between 0.5 and 1 %), the recommended target is
100 mg/dl, also obtained with pharmacological therapy in
primary prevention, in addition to lifestyle interventions.
The guidelines have focused attention on a number of
populations usually not studied in large clinical trials,
namely children, women and old persons. In children,
except in special cases, drug treatment should be conducted
over the age of 18 years [6], whereas in women and old
people, although poorly represented in large studies, there
is no reason to differentiate the therapeutic strategy in both
primary and secondary prevention than in men. Finally, the
therapeutic strategy in patients with acute coronary syn-
drome (ACS) has been widely discussed; in particular, it is
recommended that therapy with high doses of statins start
between 1 and 4 days of the SCA as recommended by
current guidelines on acute coronary syndromes, although
the importance of caution in old patients with renal or
hepatic impairment is emphasized. But the real novelty lies
in the recommendation to re-evaluate LDL levels after
4–6 weeks, and to adjust the dose for the target to maintain
[7]. Therefore, the guidelines should answer the usual
question on how long to maintain the high doses of statins,
and properly draw attention to the target rather than the
dosage.
Diet therapy and behavioral changes
Although considerable progress has been made in the
treatment and prevention of cardiovascular disease with
drug therapy, diet therapy and lifestyle remain the foun-
dation of clinical intervention. Unfortunately, there is a
wide gap between the existing dietary guidelines on how to
feed the population. The nutritional approach of the various
types of diets is often substantially different from each
other. Those used the most are as follows:
– low carbohydrate diet;
– low-fat diet;
– Mediterranean diet;
– diet recommended by scientific American societies such
as: National Cholesterol Education Program (NCEP),
ATPIII (step 1 and step 2), Therapeutic Lifestyle
Changes (TLC) and American Heart Association (AHA).
Each of these give different results for lipids and only
the low-fat diet (like dietary guidelines) and the Mediter-
ranean diet have documented a reduction in cardiovascular
events (Table 2).
The National Cholesterol Education Program (NCEP)
Adult Treatment Panel (ATP) III has affirmed the validity
of the changes in lifestyle as a therapy of choice for pri-
mary prevention. The priority is to reduce the risk of car-
diovascular disease [5]. Therefore, strategies to prevent
cardiovascular disease are based on improving the changes
in lifestyle of the population. A key role is played by
proper diet, in the context of more focused goals such as an
ideal body weight, recommended levels of LDL choles-
terol, HDL and triglycerides, a normal blood pressure and
blood glucose, physical activity and avoidance of use and
exposure to tobacco smoke.
From a behavioral point of view, sugary drinks are
strictly prohibited because they provide empty calories in
the form of simple sugars that have a rapid impact on
metabolism, insulin secretion and triglyceride synthesis. It
seems to be significant to moderate the intake of foods
Table 2 Diets compaired
Diet Nutritional features LDL HDL Triglycerides Risck
of CHD
Level of
evidence
Mediterranean Olive oil 35–40 g, walnuts \20 g, fruit,
vegetables at will (Table 4)
Reduced Increased Reduced Reduced A
Low sugar Carbohydrates 20 g at the beginning,
then till 120 g limitation of vegetables
and fruit
Reduced Increased Reduced No data B
Low fat Lipids \10 %, rich in carbohydrates Reduced Reduced Increased Reduced B
TLC (therapeutic lifestyle changes) Lipids \30 % saturated fat \7 %,
cholesterol \300 mg
Reduced Unchanged Unchanged No data A
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containing sugar or fructose, and limit the consumption of
fruit to two servings per day (150 g net per meal). Pastry
consumption must be reduced and preferably placed in the
context of a mixed meal and an appropriate count of simple
sugars. It is best to avoid the preparation of industrial sweet
as well as simple sugars containing eggs, cocoa, butter, lard
or other fat pastries such as palm oil and coconut. It should
be therefore preferable to always have moderately sweet
dishes prepared at home [6].
The high consumption of simple sugars causes an
increase in plasma triglycerides that occurs using complex
carbohydrates with suitable water-soluble fiber content.
The introduction of fiber foods has been linked to reduced
risk for chronic degenerative diseases, tumors such as
colorectal cancer, diabetes and cardiovascular disease, due
to a reduction in the levels of plasma lipids. The main
recommendation is: the optimal choice for an adult seems
to be a global consumption of 20–30 g of dietary fiber [8].
The total fat intake can be maintained in most cases at
about 30 % of the total calories by providing a 7–6 %
reduction in saturated and monounsaturated fatty acids and
replacing them with foods mostly derived from olive oil.
Therefore, the lipid-lowering cholesterol, LDL and tri-
glycerides may be controlled, as well as the palatability
of the diet and the feeling of satiety may be maintained
[9, 10].
The low blood levels of triglycerides and cholesterol and
reduced mortality from cardiovascular disease in popula-
tions with high consumption of fish have focused on fatty
acids of the x-3 series that are able to reduce the levels of
blood pressure, platelet adhesiveness, production of
thromboxane A2, levels of fibrinogen and blood viscosity,
and adhesion and migration of monocytes [11]. But their
action is primarily exerted on lipid’s/lipidic metabolism
and triglyceride levels significantly through a reduction in
their hepatic synthesis, by reducing the synthesis of APO
B, with a positive effect on post-prandial levels. The
preference of x-6 is, rather than improving the lipid profile,
to positively affect insulin sensitivity [12]. In the study by
reviewing the literature published by Harris, the effect of
x-3 fatty acids is given as a reduction in triglycerides,
which is particularly important in patients with isolated
hypertriglyceridemia or in cases where it is associated with
an increase in LDL cholesterol [13]. The report is made
more interesting with some cases of patients with severe
hypertriglyceridemia, associated with recurrent episodes of
acute pancreatitis. The treatment in those patients with x-3
fatty acids resulted in a significant reduction in serum tri-
glycerides and a reduction of recurrent pancreatitis. There
is no doubt from convincing epidemiological demonstra-
tion that a regular consumption of fish of three servings per
week is very beneficial for the treatment of hypertriglyc-
eridemia (Table 3).
The messages from the media, from nutritionists and
even physicians, concerning alcohol consumption and
mortality from cardiovascular disease are absolutely con-
flicting. It seems therefore appropriate to cite the evidence
from literature, such as observational and epidemiological
studies conducted in countries around the world that have
demonstrated an inverse correlation, with a high coefficient
(r = 0.58), between liters of wine/person/year introduced
and mortality due to cardiovascular disease [14]. It is quite
logical that other food components play a role, but the data
obtained on large cohorts of the population has an indis-
putable value. From the point of view of lipoproteins, the
main beneficial effect of alcohol is to increase HDL. A
careful study of the pathophysiology has established that
‘‘on average’’ 1 g of ethanol increases plasma HDL-C by
0.133 mg/dl (so, 30 g per day taken continuously increases
the HDL-C of 4 mg/dl); this amount of ethanol corresponds
Table 3 Effect and recommendations for foods associated with cholesterol-lowering effect
Food Source Effects Recommendation
Phytosterols Vegetable oils (e.g., corn), nuts, yogurt, milk,
margarine and other additional products
;10 % LDL 2–2.5 g/die
Soy Dry soy, soy milk, tofu, etc. ;LDL 25 g of soy protein
Soluble fiber Legumes, fruit, vegetables ;LDL,
;Total cholesterol
30–35 g/die
CHOCOLATE Dark chocolate, cocoa ;10–12 % LDL
:4–13 % HDL
;Oxidation of LDL
50–75 g (dose in the works)
Alcool Red wine :HDL
;Oxidation of LDL
;Platelet aggregation
Anti-inflammatory activity
1–2 glasses per day
Nuts Nuts ;LDL 5–7 nuts, \20 g
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to an average of one-quarter of a liter of wine per day or
700–1,000 ml of beer [15]. The other side of the coin is
that 30 g of ethanol increases triglycerides by about 6 mg/dl,
so individuals with various forms of hypertriglyceridemia
should be against the use of wine, beer, aperitifs and super-
alcoholic drinks. Apart from the effects of alcohol, red
wine can have, instead, a salutary effect in reducing car-
diovascular risk. In particular, the red wine is a very rich
source of antioxidant flavonoids, whose principal is res-
veratrol, a phenolic compound responsible for many of its
taste and sensory properties and its aging [16]. Resveratrol
is also present in red grape juice, and this could be an
alternative for those who cannot or do not wish to have
alcohol, although the amount contained in it is approxi-
mately nine times less than that contained in red wine. The
recommended amount of red wine is one or two glasses of
wine a day [17, 18].
The new guidelines for the management of dyslipidemia
ESC/EAS 2011 carefully considers how to reduce LDL
cholesterol with non-pharmacological and pharmacological
therapy. In particular, the guidelines highlight the roles of
physical activity and modest weight reduction (reduction of
about 8 mg/dl for every 10 kg of weight lost) on the levels
of LDL, while the role of favorable levels of HDL, tri-
glycerides and insulin sensitivity is of considerable impor-
tance. But the real novelty of the document will examine
the so-called ‘‘nutraceuticals’’, or the principals contained
in natural foods or commercial products that can be used in
addition to drugs to reduce cholesterol. In these guidelines,
one chapter is dedicated to functional food: the nutraceu-
ticals. This can be used either as alternatives or in addition
to lipid-lowering drugs. Several functional foods have been
found to improve health and reduce risk, including low-
ering of LDL-C [19]. FDA has recognized LDL-lowering
health claims for plant sterols (5 %), viscous fiber (4 %),
nuts and soy proteins with a combination of all four
decreasing LDL-C by 13–14 % (1). Phytosterols compete
with cholesterol for intestinal absorption, thus modulating
cholesterol levels [20]. Daily consumption of 2 g of phy-
tosterols per day can lower LDL-C by 5–10 % [21].
Phytosterols and ezetimibe can be used together without
adverse interaction and their fundamental effects on whole-
body cholesterol metabolism complement one another.
The principal phytosterols are sitosterol, campesterol and
stigmasterol. They occur naturally in oils and in smaller
amounts in vegetables, fresh fruits, chestnuts, grains and
legumes. The dietary intake of plant sterols ranges between
an average of 250 mg/d in northern Europe to 500 mg/d in
Mediterranean countries. Phytosterols have been added to
spreads and vegetable oils (functional margarine, butter
and cooking oils) as well as yogurt and other foods without
losing their cholesterol-lowering efficacy. These are usu-
ally given as sterol-enriched margarine [22]. Soy protein
(in the form of soy milk, soy meat analog or tofu) has
modest LDL-C lowering effect (3–5 %) and can be used as
a substitute for animal proteins [23, 24]; both soy and milk
protein also lower blood pressure (2 mm Hg). Thus, par-
tially replacing carbohydrate with soy or milk protein
might be an important component of nutrition intervention
strategies for the prevention and treatment of hypertension
[25]. Dietary fiber, especially soluble fiber from oat bran,
barley, beta-glucan and psyllium, is recommended for
LDL-C lowering at a daily dose of 5–15 g/d [26, 27]. This
can also be used as foods enriched with these fibers.
Epidemiological studies have consistently associated nut
consumption with reduced risk for coronary heart disease.
Nut consumption improves blood lipid levels in a dose-
related manner, particularly among subjects with higher
LDL-C or with lower BMI. The effects of nut consumption
are e dose related, and different types of nuts had similar
effects on blood lipid levels. With a mean daily con-
sumption of 67 g of nuts, the following estimated mean
reductions were achieved: LDL-C10 mg/dL and ratio of
total cholesterol concentration to HDL-C (0.24). Triglyc-
eride levels were reduced by 21 mg/dL in subjects with
blood triglyceride levels of at least 150 mg/dL [28].
Omega-3 unsaturated fatty acids from marine sources
(DHA and EPA) can lower triglyceride levels 25–30 % at a
dose of 3 g per day in people with high triglycerides, but
may increase the LDL by 5 %. Plant sources of omega-3,
such as alpha-linolenic acid present in chestnuts, some
vegetables and seed oils, are less effective in lowering
triglycerides. Policosanol is a natural mixture of long chain
aliphatic alcohols extracted primarily from sugarcane wax.
Contrary to common belief, policosanol from sugarcane,
Table 4 Genes able to modify the individual response to nutrients
Gene Function
5HTT (SLC6A4) Adapting to stress
ACE Sensitivity to salt
ADH1C Sensitivity to alcool
APOC3 Olive oil (use)
CYP1A2*1F Sensitivity to caffeine and meat
GSTM1 Crucifers (use)
IL6 General inflammation
LPL Sensitivity to saturated fat
MTHFR Metabolism vitamin B
PPARG Sensitivity to sugars and refined carbohydrates
SOD2 Oxidative stress
TNF Sensitivity to nickel
VDR Metabolism of vitamin B
LCT Sensitivity to lactose
DQ2/8 (6 GENI) Sensitivity to gluten (Celiac disease)
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rice or wheat germ has no beneficial effect on lipids [29].
Red rice yeast (RYR) is a source of fermented pigment
used in China as a food colorant and flavor enhancer for
centuries. It can lower LDL-C by a statin-like mechanism,
but the various preparations have markedly different con-
tent of biologically active ingredients, predisposing to
serious toxicity to the liver, kidneys and muscles. Other
herbal and natural agents that have been considered to
lower cholesterol remain controversial. These include po-
licosanol, flaxseed, eggplant extract, garlic, gugulipid and
chromium. Finally, after diet therapy an evaluation must be
made after 6 months, before starting drug treatment. This
will allow maintaining the normalization of plasma levels
with the lowest possible dose of the drug, and avoiding the
collateral effects inherent in most of the molecules with
lipid-lowering action [30].
Conclusions
Many studies demonstrated the effectiveness of good diet
on the reduction of lipid, but the problem is how to
implement the grip in the total sense in the general popu-
lation and dyslipidemic patients.
In recent years, many studies have been conducted to
evaluate the interactions between genes and diet. Research
in the field of nutrition will be guided through the nutrient–
gene interactions, the elucidation of the biochemical
mechanisms of control and characterization of the indi-
vidual response to dietary manipulations. This new possi-
bility that genetics applied to nutrition makes available to
us has given birth to a new branch of medicine: nutrige-
netics (see Table 4) [31]. The final approach could lead to
the concept of gene–diet interaction in addition to the
metabolic unit in the real world. Scientific research of
nutrigenetics has just begun, but the potential of specific
dietary recommendations based on genotype. It should
increase the basis of further correlations between poly-
morphisms and cardiovascular disease [32].
Actually, awareness of the population’s nutritional sta-
tus, knowledge of foods and suitable portions might
increase their adherence to diet, but a healthy future also
needs to adopt other necessary measures including gov-
ernment facilities, schools, food manufacturers, restaurants
and strategies that relate to education, production, com-
position and distribution of food [33]. In recent years,
various types of diets have been implemented on patients
such as low-fat diet, low carbohydrate and the Mediterra-
nean diets. Even better results on lipids have been shown
from these diets, in addition to diets based on the recom-
mendations of the NCEP guidelines, TLC and AHA.
However, for low carbohydrate diet like Atkins, the studies
are not associated with corresponding data on morbidity,
mortality or quality of life. In addition, carbohydrate diet is
not clear yet about whether the positive effects of HDL and
triglycerides are offset by the negative one, on total cho-
lesterol and LDL, and therefore could not currently be
recommended for the prevention of cardiovascular disease.
The greater adherence to Mediterranean diet by the general
population, which is also in trial for diseases, is associated
with significant improvement in people’s health, with a
reduction of incidence and mortality due to cardiovascular
disease and cancer. Therefore, at present, given the results
of the meta-analysis and recent trials, the demonstration of
efficacy in reducing cardiovascular mortality, including the
reduction of cardiovascular risk factors (e.g., high blood
pressure) and inflammatory markers (e.g., protein C-reac-
tive), has made Mediterranean diet to be considered as a
long-term application, and also as optimal nutrition for
healthy subjects, especially for patients with hypercholes-
terolemia or at risk of ischemic coronary events. [34]. The
dietary recommendations should be associated with infor-
mation (or advice) for a healthy lifestyle, aimed at both
primary and secondary prevention, in which even physical
exercise plays an equally important role. International
guidelines suggest targets for LDL cholesterol levels to be
reached, which may require values reduced by more than
50 % in some patients. This level of reduction is difficult to
achieve with medical treatment or dietary intervention
alone. The effectiveness of a dietary treatment associated
with the Mediterranean diet and statin drug therapy has
shown excellent results, reducing by 43 % the risk of
coronary artery disease, and significantly increasing the
advantage conferred by statin therapy alone [35].
Following the guidelines of the management of dyslipi-
demia ESC/EAS 2011, drug treatment is necessary. It reaf-
firms the central and irreplaceable role of statins, and
represents the drug of choice for blood the control of cho-
lesterol. [36–38] The guidelines clearly state that the benefits
trials are independent from the type of statin and, therefore,
the choice of the latter must be considered in relation to the
entity of the reduction required in the individual patient, as
well as the efficacy and tolerability to the molecule.
The statin seems to be most effective under maximum
tolerated doses. If the desired target could not be reached,
alternative strategies or combination can be considered. In
this regard, statins may be associated with various other
drugs that lower cholesterol, in particular the combination
with ezetimibe is the best for its tolerability and efficacy.
Other combinations may be considered in relation to the
patient’s lipid profile, including omega-3 fatty acids, nia-
cin, fibrates and phytosterols.
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